A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Soft-tissue Sarcoma|Breast Cancer
Interventions: DRUG: Cyclophosphamide and JX-594 dose escalation|DRUG: Cyclophosphamide and JX-594|DRUG: Cyclophosphamide|DRUG: Avelumab and JX-594 and Cyclophosphamide
Sponsor: Institut Bergonié
Collaborators: National Cancer Institute, France|Fondation ARC|Merck Sharp & Dohme LLC|Transgene